免疫检查点治疗的未来十年
本文综述免疫检查点治疗(ICT)的现状与挑战,包括耐药机制、患者选择、免疫相关不良事件管理及合理联合策略。强调需整合临床与基础研究及反向转化研究,以识别新靶点并指导联合策略开发,从而最大化疗效并最小化毒性。
要点
- ICT可带来持久缓解并改善总生存,但仅特定瘤种的部分患者应答。
- 核心挑战包括耐药通路、患者选择、irAE管理和合理联合治疗。
- 反向转化研究整合临床与基础研究,有助于识别新靶点指导临床试验。
核心结论
- ICT可为部分癌症患者诱导持久抗肿瘤应答。
- 合理联合策略可能通过克服原发性和适应性耐药提高应答,但可能增加免疫介导毒性风险。
- 通过更好的患者选择和合理联合可提高疗效并最小化毒性。
研究设计与样本
- 本文为综述,调查当前对ICT应答与耐药机制的理解及活跃研究领域。
主要发现
- 仅特定肿瘤类型的部分患者对ICT应答。
- 近期证据提示合理联合策略可克服原发性和适应性耐药机制。
- 联合策略可能伴随免疫介导毒性风险增加。
临床怎么用
- 需聚焦临床与基础研究整合及反向转化研究以识别潜在靶点。
- 潜在靶点可指导后续临床试验,并帮助决策新型联合策略。
- 目标是最大化疗效并最小化患者毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint therapy (ICT) can provide durable clinical responses and improve overall survival. However, only subsets of patients with specific tumor types respond to ICT. Thus, significant challenges remain, including understanding pathways of resistance, optimizing patient selection, improving management of immune-related adverse events, and identifying rational therapeutic combinations. These challenges will need a focused approach encompassing both clinical and basic research, with the integration of reverse translational studies. This integrated approach will lead to identification of potential targets for subsequent clinical trials, which will guide decisions as we develop novel combination strategies to maximize efficacy and minimize toxicities for patients. SIGNIFICANCE: ICTs induce durable antitumor responses for subsets of patients with cancer. Recent evidence suggests that rational combinatorial strategies can improve response by overcoming primary and adaptive resistance mechanisms, although these may carry an increased risk of immune-mediated toxicities. This review surveys the current understanding of mechanisms of response and resistance to ICTs and active areas of investigation, and proposes a path forward to improving efficacy and minimizing toxicities through better patient selection and rational combinations.
引用
- Sharma P, Siddiqui BA, Anandhan S, et al. The Next Decade of Immune Checkpoint Therapy. Cancer Discov. 2021. PMID: 33811120. doi:10.1158/2159-8290.CD-20-1680
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。